A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SDI-118 in Elderly Male and Female Study Participants With Cognitive Decline

Summary

This is a multi-center, double-blind, randomized, placebo-controlled study to determine the safety, tolerability, and pharmacodynamics of SDI-118 in a once daily (QD) dosing regimen on elderly male and female study participants with cognitive decline at screening.

Timeline

Start

2021-09-23

Primary completion

2022-03-11

Completion

2022-03-11

Outcome

Outcome not reported

Stopped: “Development plan changed”

Drugs

Indications